ArticleCrohn's & colitis 3602025
Inflammatory Bowel Disease Care Barriers and Medication Beliefs in a Majority Hispanic Population: A Patient Survey.
Article in Crohn's & colitis 360, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data regarding barriers to inflammatory bowel disease (IBD) care in largely Hispanic populations is limited. This study evaluated barriers in Black/Indigenous/People of Color/Hispanics (BIPOC/H) and White/non-Hispanics (W/NH) with IBD. Methods: An anonymous survey was administered to adult IBD patients at Keck Medical Center of the University of Southern California and Los Angeles General Medical Center between March and October 2024. Data included the Consumer Assessment of Healthcare Providers and Systems and Barriers to Care surveys, the Medication Adherence Rating Scale-4, and the Beliefs about Medicines Questionnaire. Analyses compared BIPOC/H and W/NH patients via Results: Included were 172 of 195 eligible patients (88% response). Compared to W/NH patients, BIPOC/Hs reported delays of longer than 1 year in receiving a diagnosis, 49.6% versus 27.8% ( Conclusions: BIPOC/H patients with IBD had more delays in diagnosis, medication-related concerns, IBD-related financial difficulties, and less social/emotional support for their IBD versus W/NHs, underscoring the need for culturally sensitive care, identification and communication of emotional, and community support resources, as well as medication decision support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.